Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Departments

By What Standard Should We Manage Diabetes?

  1. Stephen Brunton, Editor-in-Chief
  1. Primary Care Metabolic Group, Los Angeles, CA
  1. Corresponding author: Stephen Brunton, sbrunton{at}pceconsortium.com
Clinical Diabetes 2018 Jan; 36(1): 12-13. https://doi.org/10.2337/cd17-0121
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

It is now a tradition for Clinical Diabetes to publish an abridged version of the American Diabetes Association (ADA)’s annual Standards of Medical Care in Diabetes. The 2018 abridged Standards appear in this issue, starting on p. 15. In it, the ADA Primary Care Advisory Group has summarized the latest clinical practice recommendations to make them more relevant to and accessible for primary care providers (PCPs).

These annually updated guidelines are the gold standard for diabetes medical management, laying out expectations for optimal care and providing opportunities to ensure the most favorable outcomes for patients. Within this year’s abridged Standards, PCPs will learn that the results of several recently completed cardiovascular outcome trials of antidiabetic agents (1–4), have reframed the goal of diabetes medical care from a focus on attaining A1C targets, to the more expansive evidence-based approach to decreasing the cardiovascular consequences of the disease. Individualized therapy and shared decision-making are still fundamental precepts of high-quality diabetes care, and the burgeoning armamentarium of therapeutic agents offer us wonderful options for pharmacological intervention, particularly as we garner a greater understanding of the core physiological defects associated with the diabetic state.

Since the Standards were first published in 1989, there have been multiple updates, each recognizing the consensus of the day. We have come to understand that, in addition to failing β-cells, insulin resistance plays a crucial role. We now accept that there are multiple dysfunctional aspects of the disordered diabetic physiology, and with that understanding have come new therapies targeting these various dysfunctions.

But how should we use these medications? In which order? Can our patients tolerate the side effects? Will these agents cause hypoglycemia? What about their costs and inclusion in insurance formularies? The Standards provides a framework for evaluating all of these considerations, as well as strategies to address them. Diabetes is personal, and these recommendations are personalized.

Although many PCPs state that they abide by ADA recommendations, their knowledge of the details may in some cases be sparse. For generalists, this is perhaps understandable, given that there are literally thousands of guidelines directed to primary care that reflect the breadth of our practice. It is difficult to be an expert in all of the conditions we treat. However, given the increasing prevalence of diabetes and its complexity, it is incumbent on us to have a working knowledge of these comprehensive guidelines. The 2018 Standards represent the best of our current thinking about and understanding of diabetes. They contain a review of all available therapeutic options and guidance on when and how best to use them. The Standards are a resource for reference and a guide for all aspects of diabetes management.

As PCPs, we have reason to be optimistic. Although the pandemics of both diabetes and obesity are increasing, we have more tools available now than ever before to prevent and treat these diseases.

Duality of Interest

No potential conflicts of interest relevant to this article were reported.

  • © 2018 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.

References

  1. 1.↵
    1. Marso SP,
    2. Daniels GH,
    3. Brown-Frandsen K, et al., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators
    . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322
    OpenUrlCrossRefPubMed
  2. 2.
    1. Marso SP,
    2. Bain SC,
    3. Consoli A, et al.; for the SUSTAIN-6 Investigators
    . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844
    OpenUrlCrossRefPubMed
  3. 3.
    1. Zinman B,
    2. Wanner C,
    3. Lachin JM, et al., for the EMPA-REG OUTCOME Investigators
    . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Neal B,
    2. Perkovic V,
    3. Mahaffey KW, et al., for the CANVAS Program Collaborative Group
    . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657
    OpenUrl
View Abstract
PreviousNext
Back to top
Clinical Diabetes: 36 (1)

In this Issue

January 2018, 36(1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Clinical Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
By What Standard Should We Manage Diabetes?
(Your Name) has forwarded a page to you from Clinical Diabetes
(Your Name) thought you would like to see this page from the Clinical Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
By What Standard Should We Manage Diabetes?
Stephen Brunton
Clinical Diabetes Jan 2018, 36 (1) 12-13; DOI: 10.2337/cd17-0121

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

By What Standard Should We Manage Diabetes?
Stephen Brunton
Clinical Diabetes Jan 2018, 36 (1) 12-13; DOI: 10.2337/cd17-0121
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Duality of Interest
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Departments

  • Case Reports on Diabetes-Related Outcomes for Pregnant Women in the National Diabetes Prevention Program
  • Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients
  • Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
Show more Departments

Editorial

  • Telemedicine: The 2020 House Call
  • Black Diabetic Lives Matter
  • COVID-19 and Diabetes
Show more Editorial

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Abridged Standards of Care
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.